Samsung Biologics Shares Rally on Strong Growth: Key Insights Samsung Biologics stays a Buy: despite labor, legal, and quality recall risks, 2026.03 revenue rose 25.8% YoY and operating profit 35.0% YoY, supporting margin resilience and upside. 2026년 06월 02일 English
Hyundai Mobis Stock Repriced Faster: Key Opportunity Hyundai Mobis is rated a Buy as the market rapidly revalues its physical AI and tech/order momentum, despite year over year net profit decline. 2026년 06월 01일 English
Samsung Electro-Mechanics Earnings Rebound Accelerates Profit: Key Outlook Samsung Electro-Mechanics gets a Buy as revenue rose 16.4% and operating profit surged 108% YoY, driven by improving margins and AI demand, though valuation risk remains. 2026년 05월 14일 English
Naver Stock Reassessed After Earnings Dip: Valuation Insight Naver stock is rated Buy as revenue and operating profit grow, but net income fell sharply due to headline risk from regulation, AI monetization shifts, and deal friction. 2026년 05월 11일 English
Samsung Electro-Mechanics Shares Rise on AI Parts Boom: Key Insight Samsung Electro-Mechanics shows strong AI-linked growth with revenue up 16.4% YoY and operating profit up 108% YoY; analysts rate it Buy, but investors must watch net income conversion versus a 35x valuation. 2026년 05월 07일 English
